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Summary
 
The activation of endothelium is important in recruiting neutrophils to sites of inflammation
and in modulating their function. We demonstrate that conditioned medium from cultured,
activated endothelial cells acts to significantly delay the constitutive apoptosis of neutrophils,
resulting in their enhanced survival and increased phagocytic function. The antiapoptotic activ-
ity is, in part, attributable to granulocyte/macrophage colony-stimulating factor (GM-CSF) se-
creted by activated endothelial cells. The in vivo relevance of these findings was investigated in
a cytokine-induced model of acute meningitis in mice. Peripheral blood neutrophils (PBNs)
from mice with meningitis exhibited a delay in apoptosis compared with untreated mice. Fur-
thermore, neutrophils recovered from the inflamed cerebrospinal fluid (CSF) exhibited en-
hanced survival compared with neutrophils isolated from the peripheral blood of the same ani-
mals. In unchallenged GM-CSF–deficient mice, the apoptosis of circulating PBNs was similar
to wild-type animals; however, after cytokine-induced meningitis, the delay in neutrophil apop-
tosis typically observed in wild-type mice was attenuated. In contrast, the apoptosis of neutro-
phils recovered from the CSF of mice of both genotypes was comparable. Taken together,
these studies suggest that neutrophil apoptosis is regulated during an inflammatory response, in
both intravascular and extravascular compartments. GM-CSF released by activated endothe-
lium can act to increase neutrophil survival and function in the peripheral blood, whereas other
factor(s) appear to perform this function in the extravascular space.
Key words: neutrophil • apoptosis • endothelium • granulocyte/macrophage
colony-stimulating factor • inﬂammation
 
C
 
irculating neutrophils have a half-life of only 6–10 h
and execute a constitutive program of cell death, after
which they are cleared in the spleen (1, 2). The onset of
apoptosis is associated with the loss of several important
neutrophil functions, including adhesion and phagocytosis
(3, 4). The programmed cell death of neutrophils can be
delayed in vitro
 
 
 
by inflammatory mediators such as GM-
CSF, IL-6, and bacterial endotoxin (5–7). Indeed, experi-
mental studies using labeled neutrophils suggest that the life
span of extravasated neutrophils is considerably longer than
blood neutrophils: 24 h after the onset of an inflammatory
reaction, large numbers of neutrophils are still present at
the inflamed site long after the cessation of neutrophil in-
flux, typically noted at 1–4 h (1, 2). In humans, a delay in
apoptosis of circulating neutrophils has been noted in pa-
tients with burns (8), sepsis (9), or the systemic inflamma-
tory response syndrome (10) and may contribute to the en-
hanced neutrophil accumulation and inflammatory injury
observed in these clinical settings. This enhancement in
neutrophil survival presumably allows them to function
more effectively at sites of inflammation. However, once
they have completed their functions, an orderly elimination
of neutrophils is essential for the resolution of inflamma-
tion. The latter process occurs by the apoptosis of neutro-
phils in situ followed by their rapid removal by macrophages
and other phagocytes (11). We and others have shown that
neutrophil phagocytosis of opsonized particles significantly
accelerates apoptosis (12, 13). In particular, phagocytosis
via the leukocyte adhesion receptor CD11b/CD18, a 
 
b
 
2-
integrin, causes an acceleration of apoptosis which is de-
pendent on oxygen radicals generated via NADPH oxidase
(12). This represents an effective mechanism of removing
extravasated neutrophils that have reached the end of their
useful life span, thereby preventing the release of their po-
tentially histotoxic contents.
 
Part of this work was presented previously in abstract form (Coxon, A.,
T. Tang, and T.N. Mayadas. 1998. 
 
FASEB J.
 
 12[No. 5, Pt. II]:4499). 
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Endothelial cells are strategically positioned to regulate
neutrophil accumulation in inflamed tissues. This accumu-
lation is a balance of neutrophil recruitment and clearance.
Activated endothelial cells recruit neutrophils through the
release of chemoattractants and by expressing leukocyte ad-
hesion receptors, such as the selectins and IgG superfamily
members on their surface (for a review, see reference 14).
Endothelial cells have also been implicated in the delay of
apoptosis of both neutrophils and lymphocytes, and thus
potentially function to increase the number of these leuko-
cytes at sites of inflammation as well as prolong their life
span in the peripheral blood. In vitro, LPS-activated neu-
trophils that had transmigrated through an unactivated en-
dothelial cell monolayer had a delay in apoptosis that was
ascribed to a CD11b/CD18-mediated adhesion event (15).
In another report, an endothelial-mediated delay in lym-
phocyte apoptosis was attributed to IL-6 secreted by LPS-
activated endothelial cells (16).
In this study, we show that IL-1
 
b
 
 and TNF-
 
a
 
–activated,
but not unactivated, endothelial cells play a significant role
in delaying neutrophil apoptosis in vitro, and that this delay
results in the retention of an important neutrophil function,
phagocytosis of opsonized particles. Furthermore, we dem-
onstrate that GM-CSF released by the activated endothe-
lium is responsible for the delay. We examined neutrophil
apoptosis and the role of GM-CSF, in vivo, in a model of
murine meningitis. This model is induced by the lumbar
injection of the human cytokines IL-1
 
b
 
 and TNF-
 
a
 
 and
leads to rapid neutrophil accumulation in the cerebrospinal
fluid (CSF)
 
1
 
 (17). The peripheral blood neutrophils (PBNs)
of mice subjected to cytokine-induced meningitis exhib-
ited a delay in apoptosis compared with uninjected mice.
Furthermore, neutrophils that had accumulated in the CSF
had a further delay in apoptosis compared with PBNs from
the same animals. An antiapoptotic activity was detected in
the CSF of mice subjected to cytokine-induced meningitis
but not in the CSF of untreated mice, suggesting that it was
a soluble, cytokine-inducible substance. Studies in GM-
CSF–deficient mice demonstrated that GM-CSF contrib-
uted to the delay in apoptosis of PBNs but was not essential
for the further delay in apoptosis of extravasated neutro-
phils, despite the presence of GM-CSF in the CSF com-
partment. Our in vitro studies, together with our in vivo
observations, suggest that the activated endothelium which
is at the blood–tissue interface plays a crucial role in delay-
ing neutrophil apoptosis. Furthermore, we show that GM-
CSF plays a role in delaying the apoptosis of circulating
neutrophils, whereas other unidentified soluble factors are
essential for the further delay of apoptosis observed in ex-
travasated neutrophils.
 
Materials and Methods
 
Mice.
 
Age-matched wild-type and CD11b/CD18-deficient
mice (12) of the pure 129Sv strain were bred and maintained in a
virus antibody-free facility at the Longwood Medical Research
Center, Harvard Medical School. GM-CSF–deficient mice of the
129Sv/C57Bl6 mixed background and their age-matched wild-
type counterparts (18) were provided by Dr. Lloyd Old (Ludwig
Institute for Cancer Research, New York Branch at Memorial
Sloan-Kettering Cancer Center, New York, NY). The GM-
CSF–deficient mice used in our study were 6–8-wk-old males
and showed no pulmonary pathology (18) or elevated PBN
counts. These mice were housed in the specific pathogen-free fa-
cility at the Memorial Sloan-Kettering Cancer Center until they
were shipped to the quarantine facility of Harvard Medical
School, where they were housed briefly.
 
Cytokine-induced Meningitis and Isolation of Murine Neutrophils.
 
Cytokine-induced meningitis was performed essentially as de-
scribed by Tang et al. (17). Mice were injected with IL-1
 
b
 
/
TNF-
 
a
 
 by lumbar puncture at vertebrate level L-1 or L-2 and,
after 4 h, exsanguinated, and CSF was retrieved from the poste-
rior fossa by aspiration into glass capillaries, as described by Grif-
fin (19). CSF from each mouse was placed directly into Poly-
HEME (Sigma Chemical Co.)-coated wells containing IMDM
and 5% FCS, since in our experience these cells rapidly adhere to
plastic or glass. 2 
 
3 
 
10
 
5
 
 cells/well from each mouse were plated
in duplicate and incubated at 37
 
8
 
C, 5% CO
 
2
 
. Peripheral blood
samples were collected by retroorbital puncture in tubes containing
a final concentration of 5 mM EDTA. PBNs were isolated from the
anticoagulated blood pooled from two to three animals by density
centrifugation using NIM2 gradients (Cardinal Associates), as de-
scribed previously (12), and were 
 
.
 
95% pure. Alternatively, 300
 
m
 
l of whole blood from individual mice was subjected to two
rounds of RBC lysis with 0.2% NaCl and resuspended in IMDM,
5% FCS. 2 
 
3 
 
10
 
5
 
 cells/well were incubated at 37
 
8
 
C. Neutrophil
apoptosis was assessed by morphological criteria, and viability was
assessed by trypan blue exclusion. To determine if GM-CSF was
present in the CSF of mice, CSF was isolated from untreated and
cytokine-injected mice. The CSF was harvested 2 h after injec-
tion of IL-1
 
b
 
/TNF-
 
a 
 
because very few leukocytes have transmi-
grated into the CSF at this time point (17). The retrieved CSF
was centrifuged to remove any cells present, and the concentration
of GM-CSF was determined by ELISA (Endogen).
 
PMN Transendothelial Cell Migration Assay.
 
Human umbili-
cal vein endothelial cells (HUVECs) were used at confluence on
transwell inserts coated with human fibronectin (Becton Dickin-
son Labware). The bottom chamber was coated with polyheme
to prevent adherence of PMNs to the plastic (12). Endothelial
cells were treated with human recombinant IL-1
 
b
 
 (10 U/ml;
Genzyme) and TNF-
 
a
 
 (50 ng/ml; Genzyme). The monolayer
was washed four times with white cell medium (WCM: HBSS
without Ca
 
2
 
1
 
 or Mg
 
2
 
1
 
, 0.5% BSA, 25 mM Hepes, pH 7.35).
Human PBNs, isolated from normal donors, were resuspended in
WCM at 5 
 
3 
 
10
 
6
 
 PBNs/ml. 2.5 
 
3 
 
10
 
6
 
 PBNs were added to the
top chamber of the transmigration chamber, and the chemoat-
tractants FMLP (Sigma Chemical Co.) or leukotriene B
 
4 
 
(LTB
 
4
 
;
Biomol Research Labs, Inc.) or buffer alone was added to the
bottom chamber. Transmigration of neutrophils was allowed to
proceed for 1 h at 37
 
8
 
C. Control samples contained neutrophils
in WCM or WCM plus the chemoattractant used in the transmi-
gration assay, and were placed in polyheme-coated wells for 1 h
at 37
 
8
 
C. Neutrophils that had transmigrated into the lower
chamber and control samples were collected, spun down, resus-
pended in IMDM plus 5% FCS, plated in polyheme-coated wells
 
1
 
Abbreviations used in this paper:
 
 CSF, cerebrospinal fluid; HUVEC, human
umbilical vein endothelial cell; LTB
 
4
 
, leukotriene B
 
4
 
; NF-
 
k
 
B, nuclear
factor 
 
k
 
B; PBN, peripheral blood neutrophil; WCM, white cell medium. 
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at 2 
 
3
 
 
 
10
 
5
 
 PBNs/well, and placed at 37
 
8
 
C, 4% CO
 
2 
 
(time 0 h).
All samples were plated in duplicate, and apoptosis was assessed
(see below) after 6 and 8 h in culture.
 
Neutrophil Coincubations with Endothelial Cells or Endothelial-
derived Conditioned Medium.
 
HUVECs were plated in 24-well
plates coated with gelatin and were used at confluence 48 h after
plating. Actinomycin D (Calbiochem) and cycloheximide (Sigma
Chemical Co.) were used at 12 
 
m
 
M and 50 
 
m
 
g/ml, respectively.
The proteasome inhibitors MG132 and lactacystin (Calbiochem)
were used at 20 and 40 
 
m
 
M, respectively. Calpain Inhibitor II
(Calbiochem) was used as a negative control peptide in these ex-
periments. The HUVEC monolayer was pretreated with these
reagents for 1 h before the addition of cytokines, and then
washed four times with WCM. The endothelial cells were then
incubated with 5 
 
3 
 
10
 
6
 
 isolated neutrophils in WCM or with
WCM alone to collect factors released into the medium. In the
latter case, the conditioned medium was removed and incubated
with fresh 2.5 
 
3 
 
10
 
6
 
 neutrophils for an additional 1 h. Neutro-
phils were collected, spun down, and resuspended in IMDM, 5%
FCS. In experiments where neutrophils were cultured in the
continuous presence of conditioned medium, the medium was
harvested in IMDM. The conditioned medium was then supple-
mented with 5% FCS and incubated with neutrophils at 37
 
8
 
C
from 6 to 24 h. In all cases, 2.0 
 
3 
 
10
 
5
 
 cells in 500 
 
m
 
l medium
were plated in polyheme-coated wells, and 6 or 18 h after plating
aliquots were assessed for apoptosis, as described below.
 
Assessment of Apoptosis.
 
Small aliquots of each sample (100
 
m
 
l) were removed and cytospun onto slides. Cytospin prepara-
tions were fixed in methanol, stained with Wright-Giemsa, and
examined by oil immersion light microscopy at a final magnifi-
cation of 1,000
 
3
 
. The percentage of apoptotic neutrophils was
determined by counting the number of cells showing features as-
sociated with apoptosis (chromatin condensation and fragmented
nuclei). At least 200 cells per slide were counted without prior
knowledge of the sample. We and others have previously dem-
onstrated that morphological assessment of neutrophil apoptosis
closely correlates with results obtained using other methods to
assay apoptosis, such as propidium iodide staining, annexin V
binding, and decreased surface CD16 expression (12, 20). The
data were tabulated as percentage of control apoptosis (percent-
age of apoptosis occurring in PMNs that had been incubated
with endothelial cells, divided by the percentage of apoptosis in
control samples). Control refers to samples which were subjected
to the same experimental treatment but without any contact
with the endothelial cell or conditioned medium from activated
endothelial cells. We found this necessary because the rate of
spontaneous neutrophil apoptosis varies from donor to donor
(10–60% at 6 h). Apoptosis was also assessed by examining the
percentage of unfixed cells able to bind annexin V and exclude
propidium iodide (Apoptosis Detection kit from R&D Systems,
Inc.). Assays were performed as outlined in the manufacturer’s
instructions and analyzed by flow cytometry using a FACScan™
(Becton Dickinson).
 
Neutrophil Phagocytosis Assay.
 
Phagocytosis of complement-
opsonized Oil-red-O was measured as we have described previ-
ously (12). Serum opsonization of Oil-red-O particles was per-
formed as described previously (21). In brief, 4 
 
3
 
 10
 
6 
 
cells were
incubated with 100 
 
m
 
l of the serum-opsonized particles in a total
volume of 500 
 
m
 
l of Dulbecco’s PBS, with or without 1 mM
N-ethyl-maleimide (NEM), an inhibitor of phagocytosis. Cells
were washed, and the red dye was extracted using dioxane and
quantified at OD
 
525
 
. The rate of phagocytosis was calculated as
micrograms of Oil-red-O per 10
 
6
 
 PMNs per minute.
 
Immunodepletion Experiments and Measurement of GM-CSF.
 
HUVECs were activated with IL-1
 
b
 
/TNF-
 
a
 
 for 90 min, the
cells were washed four times to remove the cytokines, and condi-
tioned medium was collected after an additional 90 min. A neu-
tralizing polyclonal antibody directed against human GM-CSF
(Genzyme) bound to Sepharose–protein A was added to the con-
ditioned medium at 100 
 
m
 
g/ml. A rabbit IgG, similarly coupled
to Sepharose, was used as a negative control. The samples were
incubated overnight at 4
 
8
 
C. The antibody-bound Sepharose was
removed from the supernatant by centrifugation at 12,000 
 
g
 
 for
10 min. Human PMNs were incubated in the medium for 18 h,
and the percentage of apoptotic PMNs was assessed. The concen-
tration of GM-CSF present in conditioned medium was mea-
sured by ELISA (Genzyme) before and after immunoadsorption.
Human recombinant GM-CSF (Genzyme) was used at concen-
trations of 20–500 pg/ml.
 
Statistical Analysis.
 
Data are presented as average 
 
6 
 
SEM.
Statistical significance was assessed by unpaired Student’s 
 
t
 
 test.
 
Results
 
Neutrophils Transmigrated into the CSF of Mice after Cytokine-
induced Meningitis Have a Significant Delay in Apoptosis Compared
with Circulating PBNs.
 
We have previously developed a
model of acute, cytokine-induced meningitis in mice. In
this model, significant accumulation
 
 
 
of leukocytes (
 
.
 
95%
neutrophils) in the CSF occurs 4 h after introduction of
human IL-1
 
b
 
/TNF-
 
a 
 
into the subarachnoid space by lum-
bar puncture. Accumulation of leukocytes is dependent on
neutrophil–endothelial interaction, as mice deficient in P-
and E-selectins displayed an almost complete inhibition in
CSF leukocyte influx (17). We used this model to assess
apoptosis of neutrophils during inflammation in vivo. Neu-
trophils that had accumulated in the CSF 4 h after lumbar
injection of IL-1
 
b
 
/TNF-
 
a
 
 were harvested, and PBNs
were purified by density centrifugation from whole blood
obtained from the same animals at the same time point.
The neutrophils were placed in culture, and apoptosis was
assessed at subsequent times. Apoptosis of PBNs in mice
with cytokine-induced meningitis was significantly delayed
compared with those isolated from untreated mice. Fur-
thermore, in mice with meningitis, there was a significant
reduction in the percentage of apoptotic neutrophils in the
CSF compared with PBNs from the same animals (Fig. 1
A). Thus, cytokine-induced inflammation in the central
nervous system leads to a delay in apoptosis of circulating
neutrophils and a further delay in neutrophils that have mi-
grated across the endothelial–blood interface into an in-
flammatory site.
In these experiments, we routinely used density gradient
centrifugation to isolate neutrophils from murine whole
blood. To rule out the possibility that this procedure might
induce apoptosis or select for a subset of neutrophils, we
compared apoptosis in blood neutrophils isolated either by
our standard density centrifugation procedure or by two
cycles of hypotonic lysis of RBCs in samples of anticoagu-
lated whole blood. A 0.3-ml blood sample obtained from a
mouse with meningitis yielded 
 
.
 
80% neutrophils com-
pared with 
 
.
 
95% in neutrophils isolated by density gradi- 
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ent centrifugation. PBNs from mice with meningitis, iso-
lated by either method, had similar levels of apoptosis after
5 h in culture (data not shown).
 
CD11b/CD18-dependent Adhesion Is Not Responsible for
the Observed Delay in Apoptosis of Transmigrated Neutro-
phils.
 
Previous studies have suggested that ligation of
CD11b/CD18 with antibodies will modulate apoptosis in
neutrophils (15, 22). To more definitively examine the po-
tential role of CD11b/CD18-dependent adhesion in our
model system, we subjected CD11b/CD18-deficient mice
and their wild-type counterparts to cytokine-induced men-
ingitis. Mice deficient in CD11b/CD18 showed no signifi-
cant difference in the numbers of neutrophils that accumu-
lated in the CSF during cytokine-induced meningitis
(Tang, T., and T.N. Mayadas, unpublished data). More-
over, there was no significant difference in the percentage
 
of spontaneous apoptotic neutrophils in samples harvested
from the CSF of wild-type and CD11b/CD18-deficient
mice and subsequently cultured for 10 h (wild-type, 2.25
 
 6
 
0.6%; and CD11b/CD18
 
2
 
/
 
2
 
, 1.2
 
 6 
 
0.34%;
 
 P 
 
5 
 
0.15).
Similarly, neutrophil apoptosis in PBNs was comparable
between wild-type and CD11b/CD18-deficient mice
(wild-type, 12.83
 
 6 
 
2.13%; and CD11b/CD18
 
2
 
/
 
2
 
, 12.4
 
 6
 
2.67%;
 
 P 
 
5 
 
0.91). Thus CD11b/CD18-dependent adhe-
sion does not appear to play a role in the delayed apoptosis
observed in extravasated neutrophils, or PBNs, during this
model of cytokine-induced meningitis.
 
CSF Retrieved from Mice Subjected to Cytokine-induced
Meningitis, but Not Untreated Mice, Exhibits Antiapoptotic Ac-
tivity In Vitro.
 
To determine whether antiapoptotic fac-
tor(s) are released into the extravascular compartment in
vivo, mouse PBNs were incubated with medium alone,
Figure 1. PBNs and neutro-
phils extravasated into the CSF of
mice after cytokine-induced
meningitis have delayed apopto-
sis, and an activity released into
the CSF is responsible for this
delay. 129Sv wild-type mice
were subjected to cytokine-
induced meningitis by injection
of IL-1b/TNF-a by lumbar
puncture or were left untreated
(A). After 4 h, CSF containing
leukocyte infiltrate was collected
from each mouse (n 5 6). PMNs
represented  .90% of the cells
present. Peripheral blood was
pooled from two groups of two
mice which had been subjected
to meningitis, and two groups of
two untreated mice. PMNs from
each CSF (PMN/CSF) and pe-
ripheral blood neutrophil (PBNs)
samples were cultured in dupli-
cate, and neutrophil apoptosis
was assessed at the indicated
times (*P , 0.005, #P , 0.02 at
both time points). (B) Represen-
tative cytospins of the 5-h time
point of PMNs from the CSF,
and PBNs from cytokine-
injected mice are shown. Apop-
totic neutrophils are indicated by
arrows. In a separate experi-
ment, CSF was harvested from
untreated mice and from mice 2 h
after induction of meningitis (C).
The isolated CSF was centri-
fuged to remove any cells that
might be present; importantly, at
this early time point very few
neutrophils are present in the
CSF. PBNs from untreated mice
were cultured in the CSF or me-
dium for 4 h. The neutrophils
were then diluted with medium,
and apoptosis was assessed after
an additional 5 h. n 5 3 individ-
ual experiments; *P , 0.05 com-
pared with CSF/untreated mice. 
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CSF harvested from untreated mice, or CSF from mice 2 h
after cytokine induction of meningitis. The 2-h time point
was chosen because very few neutrophils are present in the
CSF at this time point (17), thus diminishing the potential
contribution of neutrophil-derived factors to the measured
antiapoptotic activity. CSF from mice with meningitis
caused a significant reduction in the spontaneous apoptosis
of isolated PBNs in culture, whereas CSF from untreated
mice had little effect (Fig. 1 C). These studies indicate that
the normal constituents of the CSF do not delay apoptosis,
but rather that cytokine activation leads to an accumulation
of antiapoptotic factors into the CSF. The IL-1b/TNF-a
injected into the CSF by lumbar puncture was not respon-
sible for the observed delay in neutrophil apoptosis, since
direct IL-1b/TNF-a treatment of PBNs in vitro led to
slightly elevated levels of apoptosis compared with PBNs
cultured in medium alone (data not shown).
Cytokine-activated Endothelial Cell Monolayers Significantly
Delay Apoptosis of Transmigrated Neutrophils: Endothelial
Cell–Neutrophil Coculture Is Sufficient. Endothelial cells are
uniquely situated to regulate apoptosis of circulating neu-
trophils in the blood, as well as those transmigrated into the
extravascular space. Therefore, we examined the ability of
cytokine-activated endothelial cells to modulate neutrophil
apoptosis in an in vitro model of transmigration. Ca21 and
Mg21 are omitted from the buffers so as to preserve the in-
tegrity of the activated endothelial cell monolayer during
coculture with neutrophils (23, 24). Neutrophils were al-
lowed to transmigrate across untreated or IL-1b/TNF-a–
treated HUVECs plated in transwells, in the presence or
absence of chemoattractants in the bottom chamber. Trans-
migrated neutrophils were removed, placed in fresh me-
dium, and after 6 h incubation, apoptosis was assessed.
Neutrophils that had transmigrated across cytokine-acti-
vated endothelial cells had a significant reduction in apop-
tosis compared with control neutrophils which were simi-
larly treated but were not exposed to endothelial cells (Fig.
2 A). Transmigration across unactivated HUVECs in re-
sponse to FMLP attenuated apoptosis to a much lesser ex-
tent than cytokine-activated HUVECs, suggesting that the
endothelial cell–derived antiapoptotic activity is cytokine
inducible.
To determine if transmigration was necessary for this ef-
fect or if contact with the endothelial cells was sufficient,
neutrophils were cocultured for 1 h with HUVEC mono-
layers in tissue culture dishes, and then recovered and cul-
tured for 6 h, as above. Neutrophils incubated with unacti-
vated endothelial cells had a slight delay in apoptosis,
Figure 2. Cytokine-activated endothelial cells significantly delay neutrophil apoptosis, and inhibition of de novo synthesis abrogates expression of the
antiapoptotic activity. (A) Neutrophils were allowed to transmigrate through untreated (2) or IL-1b/TNF-a–activated (Cyt.EC) HUVEC monolayers.
Buffer alone or buffer plus the chemoattractants FMLP or LTB4 were included in the bottom chamber of the transwell. Neutrophils incubated with un-
treated HUVECs transmigrated in response to FMLP in the bottom chamber. Control neutrophils were incubated in the presence or absence of the re-
spective chemoattractant, without endothelial cells. (B) Neutrophils were cocultured with HUVEC monolayers for 1 h after HUVECs were stimulated
with IL-1b/TNF-a for the indicated times. 214 wo indicates that 2 h cytokine–treated HUVECs were washed, incubated for 4 h without cytokines,
and then incubated with neutrophils for 1 h. For A and B, *P , 0.005 and #P , 0.05 compared with untreated HUVEC monolayers. (C) Endothelial
cells were pretreated with 12 mM actinomycin D (1 Act.D) or 50 mg/ml cycloheximide (1 CX) for 1 h, and IL-1b/TNF-a was added for an additional
1 h. The monolayer was washed, and neutrophils were added for 1 h. #P , 0.05 compared with IL-1b/TNF-a. For A, B, and C, neutrophils were re-
covered after transmigration or coculture, and apoptosis was assessed 6 h after culturing in fresh medium. Data are expressed as percentage of apoptosis of
control neutrophils (% control) to account for the donor variability in the amount of spontaneous apoptosis after 6 h. n 5 4 experiments.928 Activated Endothelial Cells Delay Neutrophil Apoptosis
whereas IL-1b/TNF-a–treated endothelial cells resulted in
a much greater delay in apoptosis (Fig. 2 B). A significant
delay in neutrophil apoptosis was detectable after as little as
0.5 h of IL-1b/TNF-a activation and was manifested over
an 18-h period of cytokine stimulation. If endothelial cells
were cytokine treated for 2 h, followed by a 4-h “chase in-
cubation” without cytokines, antiapoptotic activity was no
longer detectable. Therefore, these endothelial-derived
“antiapoptotic” factor(s) appear to be rapidly downregu-
lated after cytokine withdrawal.
Expression of Endothelial Antiapoptotic Factor(s) Is Dependent
on De Novo Protein Synthesis and Activation of Nuclear Factor
kB and the Stimulus Used to Activate Endothelial Cells. Cy-
tokine-stimulated HUVECs pretreated with actinomycin
D, an inhibitor of transcription, no longer delayed the apop-
tosis of neutrophils during coculture experiments. In addi-
tion, pretreating cytokine-stimulated HUVECs with cyclo-
heximide, an inhibitor of protein synthesis, also attenuated
the delay (Fig. 2 C). Therefore, the expression of the anti-
apoptotic factor(s) requires the transcriptional activation of
one or more endothelial genes.
In cytokine-activated endothelial cells, nuclear factor kB
(NF-kB) plays a prominent role in the upregulation of
genes encoding adhesion molecules and other proinflam-
matory products such as cytokines and growth factors (25).
To determine the role of NF-kB in the expression of the
endothelial-derived antiapoptotic factor(s), we used two
structurally unrelated inhibitors of NF-kB, lactacystin and
the peptide aldehyde MG132 (26, 27). Both of these inhib-
itors prevented translocation of NF-kB to the nucleus at
the concentrations used, as assessed by gel shift analysis
(data not shown). Treatment of IL-1b/TNF-a–stimulated
endothelial cells with 40 mM lactacystin decreased the de-
lay in neutrophil apoptosis to levels that were closer to
those seen with unstimulated endothelial cells (IL-1b/
TNF-a 1 lactacystin, 45.9 6 4.5%; P , 0.005 compared
with IL-1b/TNF-a alone, 10.5 6 5%; unstimulated, 76.5 6
12.5%). Similarly, treatment with MG132 attenuated the
antiapoptotic affect but to a lesser extent than lactacystin
(data not shown). These data suggest that NF-kB–depen-
dent gene regulation may be involved in the elaboration of
the antiapoptotic activity of cytokine-treated endothelial
cells.
The production of this antiapoptotic activity also de-
pends on the particular stimulus used to activate HUVECs
(Table I). For example, IL-1b treatment alone was not as
effective as TNF-a alone, and treatment with both to-
gether had a synergistic affect in delaying neutrophil cell
death. IFN-g treatment of endothelial cells resulted in a
delay of apoptosis comparable to that seen with IL-1b
alone. Of the stimuli used to activate endothelial cells, a
combination of TNF-a and IL-1b appeared to be most ef-
fective in inducing expression of the antiapoptotic activity.
Conditioned Medium from Cytokine-activated Endothelial
Cells Delays Neutrophil Apoptosis and Prevents the Associated
Loss of Neutrophil Function. To determine if the inhibition
of neutrophil apoptosis was dependent on contact with the
endothelial cells, or if the antiapoptotic factor(s) were re-
leased by the cells, conditioned medium was harvested
from untreated and IL-1b/TNF-a–treated endothelial
cells. Conditioned medium from IL-1b/TNF-a–treated
endothelial cells, but not untreated cells, significantly de-
layed neutrophil apoptosis (Fig. 3 A) to a level comparable
to that observed after coincubating neutrophils with endo-
thelial cells. Again, if cytokine-activated endothelial cells
were pretreated with actinomycin D or cycloheximide, the
observed antiapoptotic effect was attenuated; pretreatment
with the NF-kB inhibitors, MG132 or lactacystin, also at-
tenuated the delay in apoptosis to a similar extent, as seen
in Fig. 4 B (data not shown). These data suggest that the
antiapoptotic gene products are secreted and regulated at
the level of transcription, and that this is partly due to acti-
vation of NF-kB.
Experiments described so far were designed to mimic the
brief exposure of neutrophils to the endothelium during
transmigration in vivo. That is, transmigration assays or co-
incubations were done for 1 h, after which the neutrophils
were cultured in fresh medium and therefore removed
from the endothelial cell–derived antiapoptotic stimuli.
Under these conditions, neutrophil apoptosis was signifi-
cantly delayed after 6 h, as shown in Fig. 2. However, after
8 h in culture the delay in apoptosis was not as striking as at
6 h (data not shown), suggesting that the endothelial cell–
derived antiapoptotic effect was transient.  To assess
whether the continuous incubation of neutrophils with
conditioned medium from activated endothelial cells
would delay neutrophil apoptosis over a prolonged period,
neutrophils were incubated with conditioned medium for
18 h, a time period when .90% of untreated neutrophils
typically are apoptotic. Apoptosis was assessed by morpho-
logical criteria as in previous experiments, as well as by
FACS® analysis of neutrophils stained with FITC–annexin
V. Annexin V recognizes phosphatidylserine, which is in-
creased on the surface of apoptotic cells (28; Fig. 3 C). Af-
ter 18 h, neutrophils incubated with conditioned medium
Table I. Effect of Different Regimens of Endothelial Cell 
Activation on PMN Apoptosis
Endothelial cell
treatment Dose PMN apoptosis
n 5 3 % control 6 SEM
Untreated – 77.2 6 14.5
IL-1b 10 U/ml 47.3 6 1.4
TNF-a 50 ng/ml 28.3 6 3.4*
IL-1b/TNF-a 10 U/ml/50 ng/ml 17.6 6 5.5*
IFN-g 1,500 U/ml 52.9 6 9.7
IL-3 30 ng/ml 86.2 6 13.4
HUVECs were activated with various cytokines for 2 h, washed four
times, and then coincubated with human PMNs for 1 h. The PMNs
were then cultured alone for 6 h, and apoptosis was assessed.
*P , 0.05 compared with untreated.929 Coxon et al.
from IL-1b/TNF-a–stimulated endothelial cells had a dra-
matic delay in apoptosis compared with cells that were in-
cubated with conditioned medium from untreated endo-
thelial cells or fresh medium (Fig. 3 B).
Since apoptotic neutrophils lose their ability to phagocy-
tose (3), we assessed whether the endothelial cell–mediated
delay in apoptosis leads to a retention of this function. We
assessed the ability of neutrophils to phagocytose comple-
ment-opsonized particles after they were incubated in the
presence or absence of endothelial cell–derived condi-
tioned medium for 18–21 h. Neutrophils incubated with
conditioned medium derived from cytokine-treated endo-
thelial cells had a similar level of phagocytosis as freshly iso-
lated neutrophils, whereas neutrophils that were incubated
with conditioned medium from untreated HUVECs or
medium alone had lost the ability to phagocytose op-
sonized particles (Table II).
GM-CSF Released from Activated Endothelial Cells Con-
tributes to the Antiapoptotic Activity In Vitro. GM-CSF has
been previously shown to inhibit neutrophil apoptosis (5,
29) and is released by several different cell types, including
cytokine-activated endothelial cells. GM-CSF has been re-
ported in the conditioned medium of HUVECs after 4 h,
with peak activity after 24 h of IL-1b stimulation (30). To
test the hypothesis that GM-CSF was contributing to the
observed delay in neutrophil apoptosis, we first assessed
GM-CSF levels in the medium of endothelial cells under
conditions that led to the expression of antiapoptotic activ-
ity (Table III). These studies revealed that the presence of
GM-CSF correlated with the endothelial cell–derived anti-
apoptotic activity, with the exception of IL-3, which de-
layed neutrophil apoptosis but had no detectable GM-CSF,
suggesting that antiapoptotic factor(s) other than GM-CSF
were operative under this condition. GM-CSF was de-
tected as early as 0.5 h after IL-1b/TNF-a treatment, a
time point at which significant antiapoptotic activity was
observed. In addition, removal of the cytokines for 4 h be-
fore collection of conditioned medium from 2-h cytokine-
treated endothelial cells led to a loss of GM-CSF expression
and loss of antiapoptotic activity. Furthermore, combined
treatment of endothelial cells with IL-1b and TNF-a,
which led to the highest expression of antiapoptotic activ-
ity, also led to the greatest release of GM-CSF activity.
Figure 3. Conditioned medium from cytokine-stimulated HUVECs sig-
nificantly delays neutrophil apoptosis. (A) HUVECs were left untreated (2)
or were treated with IL-1b/TNF-a for the indicated times, washed, and in-
cubated with buffer alone for 1 h. The conditioned buffer was removed and
incubated with neutrophils for 1 h. The neutrophils were then put into fresh
medium, and apoptosis was assessed after 6 h. (B) Conditioned medium was
collected from untreated (unt. EC) and 1.5-h cytokine-activated (IL-1/TNF
EC) HUVECs, as described above. In contrast to conditions in A, the neu-
trophils were cultured for 18–24 h in the continuous presence of condi-
tioned medium or medium alone, and percentage of apoptosis was assessed.
The number of experiments performed is shown in parentheses. (C) Repre-
sentative cytospins are shown, and apoptotic cells are indicated by arrows.
(D) A representative FACS® analysis of samples in B that were stained with
FITC–Annexin V, which preferentially binds to apoptotic cells. *P , 0.005
compared with IL-1b/TNF-a (A) or medium alone (B).
Table II. Phagocytosis of Complement-opsonized Particles by 
PMNs Incubated with HUVEC-conditioned Medium
Time of incubation and treatment
mg Oil-red-O/106
PMNs/min
1 h medium 31.3
18 h medium 9.10
18 h 1 CM/unstimulated EC 11.25
18 h 1 CM/cytokine-stimulated EC 22.2
PMNs were incubated for 1 or 18 h in complete medium or with con-
ditioned medium (CM) harvested from unstimulated endothelial cells
(EC) or endothelial cells stimulated with IL-1b/TNF-a for 1 h. The
PMNs were then assessed for their ability to phagocytose complement-
opsonized particles. Results from one representative experiment out of
three performed are shown. Values represent the rate of phagocytosis.930 Activated Endothelial Cells Delay Neutrophil Apoptosis
To directly determine whether GM-CSF in the endo-
thelial-conditioned medium was contributing to the anti-
apoptotic activity, the conditioned medium from activated
endothelial cells was immunodepleted using a polyclonal
antibody to GM-CSF. Purified human PMNs were then
incubated in the medium for 18 h, and apoptosis was as-
sessed. Antiapoptotic activity was greatly diminished in
conditioned medium that was immunodepleted of GM-
CSF, as assessed by ELISA, whereas similar incubations
with an isotype control IgG had no effect on GM-CSF lev-
els or apoptosis (Fig. 4). Immunodepletion of GM-CSF
with an mAb  (BVD2-23B6) yielded similar results (data
not shown). Together, these studies indicate that GM-CSF
is present in the conditioned medium of activated endothe-
lial cells under conditions that lead to the expression of an-
tiapoptotic activity, and that removal of GM-CSF by im-
munodepletion leads to loss of this activity. Therefore, we
conclude that GM-CSF is primarily responsible for the de-
layed apoptosis observed in our in vitro assay system.
GM-CSF Is Required for the Apoptotic Delay Observed in
PBNs. To critically examine the contribution of GM-
CSF to neutrophil apoptosis in vivo, we used GM-CSF–
deficient mice and their wild-type counterparts. We first
isolated PBNs from untreated animals of both genotypes
and found no significant difference in the levels of apopto-
sis after culture (data not shown). We then performed cy-
tokine-induced meningitis in these mice. GM-CSF–defi-
cient mice had normal peripheral blood counts (18; data
not shown), and mice of both genotypes responded with
significant accumulation of neutrophils in the CSF (wild-
type, 1.1 6 2.7 3 106; GM-CSF2/2, 2.5 6 5.47 3 106
cells recovered in CSF). Significantly, there was a 30–40%
increase in the level of apoptosis in PBNs isolated from
GM-CSF–deficient mice compared with wild-type mice
(Fig. 5). Therefore, GM-CSF plays an important role in the
regulation of neutrophil apoptosis in the peripheral blood
only during inflammation. We observed no difference in
the percentage of apoptotic neutrophils retrieved from the
CSF of GM-CSF–deficient and wild-type mice, despite the
fact that GM-CSF was detected in the CSF of wild-type
animals (naive mice, 0 pg/ml; mice subjected to meningitis
for 4 h, 135.1 6 42.2 pg/ml). Thus, soluble factors other
than GM-CSF are responsible for increasing neutrophil
survival in the extravascular compartment.
Discussion
The localized accumulation of functional neutrophils at
sites of inflammation is pivotal in the host’s defense against
infection, and the orderly elimination of neutrophils is
equally important in resolution of the inflammatory re-
sponse. It is well recognized that the endothelium, upon
activation by various proinflammatory stimuli including cy-
tokines such as IL-1b and TNF-a, plays an active role in
recruiting leukocytes via the expression of adhesion mole-
cules and chemoattractants (31). The results reported here
establish a previously unrecognized role for the activated
endothelium in prolonging neutrophil survival and retain-
ing neutrophil functional capabilities in the context of in-
flammation, one that may have important implications for
the regulation of the acute inflammatory response. Our ob-
servations suggest two levels at which neutrophil apoptosis
Table III. Expression of Antiapoptotic Activity Correlates with 
GM-CSF Production
Endothelial treatment PMN apoptosis GM-CSF
% control 6 SEM pg/ml 6 SEM
Untreated 77.2 6 14.5 0
0.5 h IL-1b/TNF-a 19.1 6 4.8 52.9 6 9.6
5 h IL-1b/TNF-a 8.3 6 0.6 190.2 6 32.7
18 h IL-1b/TNF-a 19.7 6 6.7 297.9 6 25.2
2 h IL-1b/TNF-a 1 4 w/o 81.5 6 26.1 5.7 6 5.7
2 h IL-1b 47.3 6 1.4 23.0 6 0.1
2 h TNF-a 28.3 6 3.4 13.4 6 0.7
2 h IL-1b/TNF-a 17.6 6 5.5 93.7 6 7.4
2 h IL-3 52.9 6 9.7 0
2 h IFN-g 86.2 6 13.4 0
Conditions of endothelial treatment and the values for percentage of
apoptosis are those described in Fig. 3 B and Table I. Levels of GM-
CSF present in the conditioned medium were assessed by ELISA. Data
represent the average of three independent experiments.
Figure 4. Effect of immunodepleting conditioned medium of GM-
CSF on PMN apoptosis. Conditioned medium (CM) from IL-1b/TNF-
a–treated HUVECs was immunodepleted of GM-CSF using neutralizing
polyclonal antibodies (CM aGM-CSF). A rabbit IgG was used as nega-
tive control (CM IgG). PMNs were incubated for 18 h in the condi-
tioned medium, and the percentage of apoptotic PMNs was assessed. #P ,
0.05 compared with medium alone, and *P , 0.05 compared with CM
and CM/IgG. The amount of GM-CSF present in the conditioned me-
dium before and after immunodepletion was assessed by ELISA, and the
average (pg/ml) is shown below the respective conditions. n 5 3 experi-
ments.931 Coxon et al.
is regulated during inflammation. The first is a delayed apop-
tosis in neutrophils in the peripheral circulation, and the
second is a more substantial delay in apoptosis of neutro-
phils that have extravasated into a site of inflammation. The
endothelium is positioned to directly affect the apoptosis of
circulating neutrophils. It may also affect the apoptosis of
extravasated neutrophils, although the role of other cell
types in the tissue cannot be ruled out.
Our in vitro studies demonstrate that the antiapoptotic
activity of endothelial cells is rapidly inducible and that it is
sustained over 24 h in the presence of cytokines. However,
the activity decays in the absence of ongoing stimuli. Thus,
the antiapoptotic activity from endothelial cells may func-
tion to influence the survival of neutrophils during the ear-
liest periods of their recruitment. Furthermore, only under
conditions where neutrophil recruitment and inflammation
were ongoing would neutrophil survival be extended, since
the elaboration of the antiapoptotic factors is dependent on
cytokine stimulation of the endothelial cells. NF-kB,
which is a pleiotropic regulator of the proinflammatory ac-
tivities of endothelial cells such as leukocyte adhesion re-
ceptor expression (25), is important in the expression of
endothelial antiapoptotic activity. Thus, mechanisms regu-
lating the recruitment of neutrophils to the endothelium
also play a role in the survival of those neutrophils.
CD11b/CD18-mediated adhesion is not required for the
delay in neutrophil apoptosis in vivo, although another
study in vitro suggested that this may be the case since anti-
body cross-linking of CD11b/CD18 or CD11a/CD18 at-
tenuated neutrophil cell death (15).
We show that the antiapoptotic activity is secreted and
that it is extremely potent. The number of neutrophils that
are apoptotic after a 24-h period in culture is reduced by
80% in neutrophils that are incubated with conditioned
medium from endothelial cells compared with those incu-
bated in medium alone. The enhanced neutrophil survival
in the presence of endothelial-derived factors is associated
with a retention in the ability of the neutrophil to phago-
cytose, a principal function of these phagocytes at sites of
inflammation. Thus, endothelial cells promote the survival
of neutrophils and their function in response to cytokine
activation, thereby potentially enhancing the accumulation
of functional neutrophils at the site of inflammation. Many
recombinant forms of inflammatory mediators can inhibit
apoptosis and prolong neutrophil survival in vitro (3, 5).
Some of these, GM-CSF, IL-6, and IL-1b, are known to
be released by the activated endothelium, although the role
of these cytokines in a physiological context is not clear.
Here, we demonstrate that GM-CSF released from cyto-
kine-activated endothelial cells in vitro is responsible for
the antiapoptotic activity. Two aspects of the regulation of
GM-CSF expression observed in this study have not been
previously described (30, 32, 33). GM-CSF was released
into the medium of endothelial cells as early as 0.5 h after
cytokine activation, and IL-1b and TNF-a had a synergis-
tic effect in stimulating GM-CSF production in endothelial
cells.
The role of GM-CSF in neutrophil apoptosis in vivo
was critically examined by assessing apoptosis of neutro-
phils retrieved from both untreated GM-CSF knockout
and wild-type mice, and mice subjected to cytokine-
induced meningitis. These studies suggested that GM-CSF
has no effect on the spontaneous programmed cell death of
PBNs in untreated mice, but is responsible for delaying the
spontaneous apoptosis of PBNs during an inflammatory re-
sponse. On the other hand, the greater delay in apoptosis of
extravasated neutrophils was found to be regulated by solu-
ble factors other than GM-CSF. Thus, neutrophil apoptosis
is differentially regulated in the peripheral blood and ex-
travascular tissue, not only in terms of the extent of the de-
layed apoptosis but also in the soluble mediator(s) involved.
Data from this study, together with previous data dem-
onstrating that phagocytosis promotes neutrophil apoptosis
(12, 13), have led us to propose the following model for
Figure 5. Mice deficient in GM-CSF have less
of a delay in PBN apoptosis after cytokine-induced
meningitis than wild-type mice. Neutrophils were
isolated from the CSF and peripheral blood of eight
wild-type (WT) and eight GM-CSF–deficient
(GM-CSF2/2) mice, 4 h after cytokine-induced
meningitis. The harvested neutrophils were then
placed in culture, and apoptosis was assessed on
cytospins at the indicated time points. *P , 0.05,
#P , 0.002.932 Activated Endothelial Cells Delay Neutrophil Apoptosis
the regulation of neutrophil apoptosis during an inflamma-
tory response. The vascular endothelium actively recruits
PBNs to sites of inflammation via expression of adhesion
molecules and chemoattractant cytokines. The constitutive
cell death program in the recruited neutrophils is delayed
by antiapoptotic factors released from the endothelium, in-
cluding GM-CSF. This delay in the programmed cell death
of neutrophils during inflammation allows the neutrophil
to retain its functional capabilities. Once neutrophils have
completed their principal function, which is the phagocy-
tosis of bacteria and cellular debris, the death program is re-
engaged. It follows that defects in the regulation of neutro-
phil apoptosis could have severe consequences for the host.
Dysfunctional upregulation of the endothelial antiapoptotic
factor(s) could result in increased accumulation of PMNs in
the extravascular tissue and prolong the inflammatory re-
sponse, culminating in tissue damage. Alternatively, a re-
duction in the antiapoptotic activity could lead to prema-
ture apoptosis of neutrophils in the tissue, thereby
compromising host defense. Further studies of the regula-
tion of expression of the key effectors of neutrophil apop-
tosis secreted by activated vascular endothelium, including
GM-CSF and other as yet undefined mediators, should add
to an understanding of the control potential of the inflam-
matory response and the disease-related consequences.
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